Zusammenfassung
Ziel der Hochdruckbehandlung ist es, den Blutdruck zu senken und dadurch das kardiovaskuläre Risiko der Patienten zu verringern. Für diese Therapie stehen Allgemeinmaßnahmen sowie Antihypertensiva zur Verfügung. Bei der Mehrzahl der Hypertoniker gelingt es allein mit Allgemeinmaßnahmen nicht, den Blutdruck ausreichend zu senken. Bei allen Hypertonikern soll der Blutdruck auf <140/90 mmHg gesenkt werden. Bei Diabetikern, Patienten mit Niereninsuffizienz sowie bei Patienten mit Folgekrankheiten der Hypertonie und dadurch sehr hohem kardiovaskulärem Risiko ist der Zielblutdruck <130/80 mmHg. Diuretika, β-Blocker, Kalziumantagonisten, ACE-Inhibitoren und AT1-Antagonisten sind die Antihypertensiva der ersten Wahl. Die Auswahl unter diesen Substanzgruppen erfolgt auf Grund von zu erwartenden Nebenwirkungen sowie unter Berücksichtigung von Begleit- und Folgekrankheiten. Dabei sollte man in Betracht ziehen, dass der wesentliche Nutzen der antihypertensiven Behandlung auf der Blutdrucksenkung an sich beruht und dass die meisten Hypertoniker zum Erreichen des Zielblutdrucks eine Kombination von 2 oder mehr Antihypertensiva benötigen.
Abstract
The goal of antihypertensive therapy is to lower blood pressure and, by doing so, to decrease cardiovascular risk. Life style changes and drugs are available for the treatment of hypertensive patients. In order to reach the target blood pressure, most patients with hypertension need drug treatment in addition to life style changes. In all hypertensive patients, the target blood pressure is <140/90 mmHg. In patients with diabetes mellitus, with chronic renal failure as well as in patients with complications of hypertension and, thereby a very high cardiovascular risk, the target blood pressure is <130/80 mmHg. Diuretics, beta-blockers, calcium antagonists, ACE-inhibitors and angiotensin receptor blockers are the drugs of first choice in the treatment of hypertension. The selection among these drug classes has to consider probable side effects as well as accompanying diseases and complications of hypertension. One should also take into account that most of the beneficial effects of antihypertensive therapy is due to the decrease of blood pressure per se and that the majority of hypertensive patients require the combination of two or more antihypertensive drugs in order to reach the target blood pressure.
Literatur
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997
Arima H, Chalmers J, Woodward M et al.; PROGRESS Collaborative Group (2006) Lower target blood pressures are safe and effective for the prevention of recurrent stroke: The PROGRESS trial. J Hypertens 24: 1201–1208
Barnett AH, Bain SC, Bouter P et al. (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952–1961
Braunwald E, Domanski MJ, Fowler SE et al.; PEACE Trial Investigators (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351: 2058–2068
Brenner BM, Cooper ME, De Zeeuw D et al.; RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869
Casas JP, Chua W, Lukogeorgakis S et al. (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366: 2026–2033
Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366: 895–906
Deutsche Hochdruckliga (2008) Leitlinien zur Behandlung der arteriellen Hypertonie. http://www.hochdruckliga.de
Elliot WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: A network meta- analysis. Lancet 369: 201–207
Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet 362: 782–788
Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755–1762
Hou FF, Zhang X, Zhang GH et al. (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354: 131–140
Ismail AA, Medhat I, Tawfic TA, Kholeif A (1993) Evaluation of calcium-antagonist (nifedipine) in the treatment of pre-eclampsia. Int J Gynaecol Obstet 40: 39–43
Jafar TH, Stark PC, Schmid CH et al.; AIPRD Study Group (2003) Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 139: 244–252
Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359: 2417–2428
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456–1462
Lewis EJ, Hunsicker LG, Clarke WR et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860
Lindholm LH, Carlberg B, Samuelsson O (2005) Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553
Magee LA, Elran E, Bull SB et al. (2000) Risks and benefits of beta-receptor blockers for pregnancy hypertension: Overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 88: 15–26
Mancia G, De Backer G, Dominiczak A et al. (2007) Guidelines for the management of arterial hypertension. J Hypertens 25: 1105–1187
Medical Research Council Working Party (1985) MRC trial of mild hypertension: Principal results. BMJ (Clin Res Ed) 291: 97–104
Messerli FH, Mancia G, Conti CR et al. (2006) Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144: 884–893
Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285: 685–688
ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559
Patel A, MacMahon S, Chalmers J et al.; ADVANCE Collaborative Group (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 370: 829–840
Pepine CJ, Handberg EM, Cooper-DeHoff RM et al.; INVEST Investigators (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290: 2805–2816
Peterson JC, Adler S, Burkart JM et al. (1995) Blood pressure control, proteinuria,and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754–762
PROGRESS Collaborative Study Group (2001) Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041
Turnbull F; Blood Pressure Lowering Treatment Trialists‘ Collaboration (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362: 1527–1535
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin:
Referent für die Firmen Asche-Chiesi, Daiichi Sankyo, Pfizer und Torrent.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rahn, K. Leitliniengerechte Differenzialtherapie der Hypertonie. Internist 50, 433–441 (2009). https://doi.org/10.1007/s00108-008-2292-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-008-2292-8